Information Provided By: 
Fly News Breaks for May 8, 2018
FOLD
May 8, 2018 | 12:48 EDT
JPMorgan analyst Anupam Rama attributes today's post-earnings weakness in shares of Amicus Therapeutics to "conservative commentary" on the call related to the Pompe program. The analyst, however, does not believe that the regulatory scenarios he outlined last month for the program have fundamentally changed. Nonetheless, Rama thinks commentary on the call, particularly on timing, was perceived as cautious. Amicus shares are down 7.5% to $13.49 in midday trading.
News For FOLD From the Last 2 Days
There are no results for your query FOLD
